3 results
Approved WMOCompleted
Primary objective To investigate the safety and tolerability of CCS1477 as monotherapy and in combination.
Approved WMOCompleted
The primary objective of the main non-inferiority study is to determine the safety of TACmono starting nine months after kidney transplantation in immunologically low-risk patients in terms of BPAR-rate 15 months after transplantation compared to…
Approved WMOCompleted
Primary objectives:- Overall: Improvement of event-free survival (EFS) probabilities in childhood relapsed ALL- Randomization 1: EFS of Arm A (ALL-REZ BFM 2002) versus B (ALLR3) in SR patients- Randomization 2: Influence of epratuzumab on EFS in…